Sozinibercept |
| カタログ番号GC70936 |
Sozinibercept (OPT 302;vgx-300)は、血管新生前因子であるvegf-c / dの活性を強く阻害し、血管新生と血管漏出を阻害します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2568358-31-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Sozinibercept inhibits CNV lesion formation and vascular leakage in the mouse laser-induced model of choroidal neovascularization (CNV). Moreover, Sozinibercept exhibits comparable efficacy to Aflibercept in CNV mouse model[1][2].
Sozinibercept (intravitreal injection; once every 4 wk for 4 months) shows selective inhibition of VEGF-C/D, and inhibits diabetic retinal edema induced by streptozotocin (STZ) in the rat model, and equivalent to inhibition of VEGF-A inhibitor (Aflibercept)[3].
References:
[1]. Lashkari K, et al. VGX-300, a ‘Trap’for VEGF-C and VEGF-D, Inhibits Choroidal Neovascularization and Vascular Leakage in a Mouse Model of Wet AMD[J]. Investigative Ophthalmology & Visual Science, 2015, 56(7): 4802-4802.
[2]. Lashkari K, et al. VEGF-C and VEGF-D Blockade by VGX-300 Inhibits Choroidal Neovascularization and Leakage in a Mouse Model of wet AMD[J]. Investigative Ophthalmology & Visual Science, 2014, 55(13): 1823-1823.
[3]. Turunen T, et al. VEGF-C and VEGF-D Inhibition by VGX-300 Effectively Reduces Leukocyte Adhesion and Vascular Leakage in the STZ-Rat Model of Diabetic Retinal Edema[J]. Investigative Ophthalmology & Visual Science, 2019, 60(9): 3667-3667.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *